食管癌根治术后寡转移并非一概而论:不同器官部位预后差异显著
本研究纳入1995至2016年R0食管切除术后出现孤立实性器官复发(脑37例、肺27例、肝40例)的104例患者,比较不同复发部位的临床病理特征与生存。肺寡转移中位总生存2.41年,显著优于脑(0.95年)和肝(0.95年),校正后差异仍显著。结论认为不同复发部位表现与预后不同,肺寡转移病程更惰性,或可从更积极治疗中获益。
要点
- 肺寡转移中位总生存2.41年,优于脑和肝的0.95年(P<.001)。
- 校正患者和肿瘤特征后,脑复发风险比4.48、肝2.94,差异仍显著。
核心结论
- 食管癌术后孤立实性器官寡转移的表现和预后因部位而异。
- 肺寡转移病程更惰性,患者或可从更积极治疗中进一步改善预后。
- 不同复发部位预后的差异提示不应对所有食管癌复发采用统一的姑息治疗策略。
研究设计与样本
- 回顾性队列研究,纳入1995至2016年行R0食管切除术后出现肝、肺或脑孤立实性器官复发的患者。
- 共纳入104例患者,其中脑复发37例、肺复发27例、肝复发40例。
- 比较不同复发部位的临床病理特征和结局,采用Kaplan-Meier法和Cox比例风险模型量化总生存。
主要发现
- 肺寡转移患者中位总生存2.41年(95%CI 1.58至3.31),显著长于脑寡转移0.95年(95%CI 0.62至1.49)和肝寡转移0.95年(95%CI 0.82至1.41),P<.001。
- 校正患者和肿瘤特征后差异仍显著:脑复发风险比4.48(95%CI 2.24至8.99),肝复发风险比2.94(95%CI 1.48至5.82)。
- 尽管积极治疗使用有限,肺寡转移患者仍表现出更长的中位总生存。
临床怎么用
- 对食管癌术后复发患者应区分寡转移部位进行预后评估,而非统一按姑息治疗处理。
- 肺寡转移患者预后相对较好,可考虑更积极的局部干预以进一步改善结局。
- 脑或肝寡转移患者预后较差,治疗决策需结合部位特异性预后信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: More than one-half of patients treated with esophagectomy for esophageal cancer experience recurrence. Oligometastasis, a proposed intermediate state of isolated local or solid organ recurrence that occurs before widespread systemic disease, is a potential target for aggressive local intervention. This study investigated presentation and prognosis among solid organ recurrence sites. METHODS: Patients with isolated solid organ recurrence at the liver, lung, or brain who underwent R0 esophagectomy from 1995 to 2016 were identified. Clinicopathologic characteristics and outcomes were compared among sites of recurrence. Overall survival was quantified using the Kaplan-Meier approach and Cox proportional hazards models. RESULTS: In total, 104 patients were included (site: brain, 37; lung, 27; liver, 40). Eighty percent of liver, 51% of brain, and 44% of lung oligometastases occurred in the first 12 months after esophagectomy. Despite the limited use of aggressive therapy, patients with lung oligometastasis had significantly longer median overall survival (2.41 years; 95% confidence interval [CI], 1.58 to 3.31) than did patients with brain (0.95 years; 95% CI, 0.62 to 1.49) or liver (0.95 years; 95% CI, 0.82 to 1.41) oligometastasis (P < .001). This difference remained after patient and tumor characteristics were adjusted for (brain: hazard ratio, 4.48; 95% CI, 2.24 to 8.99; liver: hazard ratio, 2.94; 95% CI, 1.48 to 5.82). CONCLUSIONS: Presentations and prognoses differ by site of esophageal cancer recurrence. Lung oligometastases are associated with a more indolent course, and patients with these lesions may benefit from more aggressive treatment to improve their more favorable outcomes further. These differences by site of recurrence advocate for moving beyond a standardized palliative approach to all esophageal cancer recurrences.
引用
- Nobel TB, Sihag S, Xing X, et al. Oligometastases After Curative Esophagectomy Are Not One Size Fits All. Ann Thorac Surg. 2021. PMID: 33689743. doi:10.1016/j.athoracsur.2021.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。